ATX-898

ATX-898 is a small molecule (registry lists it as a drug; the company does not publish the modality for this code) from Antares Therapeutics. Not disclosed. The registry describes a first-in-human study of ATX-898 alone and with other anticancer drugs; no source reached names its target. Its furthest stage is phase 1, for advanced solid tumours, platinum-resistant ovarian cancer, other gynaecological cancers and HR-positive HER2-negative breast cancer (with fulvestrant plus abemaciclib or ribociclib). ClinicalTrials.gov registers it in one study linked below. Phase 1/2 study NCT07767474 recruiting; actual start 31 August 2026 (ClinicalTrials.gov). Whether it works in people has not been established unless a trial below reports it.